Inflammation in Posttraumatic Stress Disorder: Dysregulation or Recalibration?
Posttraumatic stress disorder (PTSD)
anti-inflammatory agents.
immune system
inflammation
microglia
neurobiology
Journal
Current neuropharmacology
ISSN: 1875-6190
Titre abrégé: Curr Neuropharmacol
Pays: United Arab Emirates
ID NLM: 101157239
Informations de publication
Date de publication:
07 Aug 2023
07 Aug 2023
Historique:
received:
02
11
2022
revised:
04
01
2023
accepted:
06
01
2023
medline:
8
8
2023
pubmed:
8
8
2023
entrez:
8
8
2023
Statut:
aheadofprint
Résumé
Despite ample experimental data indicating a role of inflammatory mediators in the behavioral and neurobiological manifestations elicited by exposure to physical and psychologic stressors, causative associations between systemic low-grade inflammation and central nervous system inflammatory processes in posttraumatic stress disorder (PTSD) patients remain largely conceptual. As in other stress-related disorders, pro-inflammatory activity may play an equivocal role in PTSD pathophysiology, one that renders indiscriminate employment of anti-inflammatory agents of questionable relevance. In fact, as several pieces of preclinical and clinical research convergingly sug- gest, timely and targeted potentiation rather than inhibition of inflammatory responses may actually be beneficial in patients who are characterized by suppressed microglia function in the face of systemic low-grade inflammation. The deleterious impact of chronic stress-associated inflammation on the sy- stemic level may, thus, need to be held in context with the - often not readily apparent - adaptive payoffs of low-grade inflammation at the tissue level.
Identifiants
pubmed: 37550908
pii: CN-EPUB-133424
doi: 10.2174/1570159X21666230807152051
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.